These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21942254)

  • 1. Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.
    Ferrari N; Seguin R; Renzi P
    Future Med Chem; 2011 Oct; 3(13):1647-62. PubMed ID: 21942254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.
    Séguin RM; Ferrari N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1505-17. PubMed ID: 19715448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotides: New therapeutic approaches for asthma and chronic obstructive pulmonary disease.
    Parry-Billings M; Ferrari N; Seguin R
    Curr Opin Investig Drugs; 2010 Nov; 11(11):1276-85. PubMed ID: 21157647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.
    Nyce J
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future therapies for airway mucus hypersecretion.
    Barnes PJ
    Novartis Found Symp; 2002; 248():237-49; discussion 249-53, 277-82. PubMed ID: 12568498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel signal transduction modulators for the treatment of airway diseases.
    Barnes PJ
    Pharmacol Ther; 2006 Jan; 109(1-2):238-45. PubMed ID: 16171872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
    Groneberg DA; Rabe KF; Fischer A
    Eur J Pharmacol; 2006 Mar; 533(1-3):182-94. PubMed ID: 16473346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting remodeling in respiratory inflammation.
    Knox AJ; Pang L; Zhu YM
    Curr Opin Investig Drugs; 2000 Dec; 1(4):428-34. PubMed ID: 11249695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based respiratory medicine in horses.
    Williamson KK; Davis MS
    Vet Clin North Am Equine Pract; 2007 Aug; 23(2):215-27. PubMed ID: 17616311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper.
    Roth-Walter F; Adcock IM; Benito-Villalvilla C; Bianchini R; Bjermer L; Caramori G; Cari L; Chung KF; Diamant Z; Eguiluz-Gracia I; Knol EF; Kolios AGA; Levi-Schaffer F; Nocentini G; Palomares O; Puzzovio PG; Redegeld FA; van Esch BCAM; Stellato C
    Allergy; 2019 Mar; 74(3):432-448. PubMed ID: 30353939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.